EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients

A Elif Müderrisoglu, Ayse A Sakul, Sandra Murgas, Jean J M C H de la Rosette, Martin C Michel

Frontiers in Pharmacology · 30.03.2023 · 14

DOI: 10.3389/fphar.2023.1144470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.03.2023. Verfasst von A Elif Müderrisoglu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, Istanbul Medipol University, Istanbul, Türkiye. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data indicate that OAB patients with concomitant diabetes or hypertension, known risk factors of atherosclerosis, may exhibit greater baseline OAB symptoms and slightly smaller therapeutic responses to treatment, but the impact of a combined presence of diabetes and hypertension has not been reported. Therefore, we have explored whether the combined presence of both comorbidities is associated with greater baseline OAB symptoms than that of either comorbidity alone. Secondary questions were exploration of the impact of either comorbidity on baseline symptoms, and of the impact of either comorbidity alone and their combination on therapeutic responses.

Methods

Data from two non-interventional studies applying treatment with propiverine ER 30 or 45 mg/d for 12 weeks were analyzed.

Results

Number of urgency episodes in the combination group was greater than with each comorbidity alone. The impact of comorbidities on baseline intensity of incontinence, frequency or nocturia or Patient Perception of Bladder Condition was less consistent or absent. Either comorbidity alone was associated with a smaller % improvement of symptoms, and their combination had a greater effect than either alone. However, all attenuations associated with comorbidity were small relative to the overall improvement.

Conclusions

We conclude that comorbidities of diabetes and hypertension have detectable effects on OAB symptoms and treatment responses, but the small magnitude of these alterations does not justify changing existing paradigms for the clinical management of OAB.

Schlagwörter

Stichwörter der Autor:innen

comorbiditydiabeteshypertensionnon-interventional studyoveractive bladder syndromepropiverinetreatment

Autor:innen und Institutionen

  • Department of Medical Pharmacology, Istanbul Medipol University, Istanbul, Türkiye.
  • APOGEPHA Arzneimittel GmbH, Dresden, Germany.
  • Department of Urology, Medipol Mega University Hospital, Istanbul Medipol University, Istanbul, Türkiye.
  • Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Müderrisoglu, A. E., Sakul, A. A., Murgas, S., de la Rosette, J. J. M. C. H., & Michel, M. C. (2023). Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1144470

Vancouver

Müderrisoglu AE, Sakul AA, Murgas S, de la Rosette JJMCH, Michel MC. Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1144470

BibTeX
@article{Mderrisoglu2023,
  author = {Müderrisoglu, A Elif and Sakul, Ayse A and Murgas, Sandra and de la Rosette, Jean J M C H and Michel, Martin C},
  title = {Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1144470}
}
Kostenlos starten →